CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Testing for Vector-borne Infections — Coverage and Clinical-Laboratory Criteria

Coverage and clinical-laboratory testing criteria for diagnosis of arthropod-borne infections (mosquito-, tick-, flea-, mite-borne) including recommended and non-recommended laboratory methods for multiple pathogens; applies to Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyTesting for Vector-borne Infections — Coverage and Clinical-Laboratory Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder pathogen-specific tests consistent with the listed coverage criteria and document specimen type and timing relative to symptom onset.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

20+coverage statements

10+pathogens addressed

12 wksZika NAAT window

84.2%BinaxNOW sensitivity

96.2%qPCR sensitivity (Babesia)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

IFA rickettsial limit

Coverage Criteria for Arthropod-Borne Infections

inv-01: Covered testing by pathogen

Covered when the following pathogen-specific testing and clinical context apply

Babesiosis - Covered tests: For individuals suspected of having babesiosis, a Giemsa- or Wright-stained blood smear OR NAAT meets coverage criteria.

IFA IgG or IgM for Babesia does NOT meet coverage (see exclusion node).

Babesiosis - Not covered: Use of either an IgG or IgM IFA assay for Babesia does NOT meet coverage criteria.

Chikungunya - Covered tests: For individuals suspected of chikungunya, viral culture, NAAT of serum, OR IFA for IgM during acute and convalescent phases meets coverage criteria.

Colorado tick fever (CTF) - Covered tests: For suspected CTF, virus-specific IFA-stained blood smears OR IFA for CTF-specific antibodies meet coverage criteria.

Dengue (DENV) - Covered tests: For suspected dengue, NAAT, IgM MAC-ELISA, NS1 ELISA, and confirmatory PRNT meet coverage criteria.

IgG ELISA or hemagglutination testing for DENV does NOT meet coverage.

Ehrlichiosis/Anaplasmosis - Covered tests: For suspected ehrlichiosis and/or anaplasmosis, NAAT of whole blood, IFA assay for IgG antibodies, OR microscopy for morulae detection meet coverage criteria.

IFA for IgM or standard blood culture does NOT meet coverage.

Malaria - Covered tests: For suspected malaria, rapid immunochromatographic diagnostic tests OR smear microscopy to diagnose, speciate, identify life cycle stage, and/or quantify parasitemia meet coverage; microscopy may be repeated up to three times within three days if initial microscopy is negative in suspected cases.repeat microscopy: up to 3 times within 3 days

NAAT or IFA for Plasmodium antibodies does NOT meet coverage.

Rickettsial disease - Covered tests: For suspected rickettsial disease, IFA assay for IgG antibodies meets coverage criteria (IFA testing is limited to two units as noted elsewhere).two units

Standard blood culture, NAAT, or IFA for IgM does NOT meet coverage.

Tick-borne relapsing fever (TBRF) - Covered tests: For suspected TBRF, dark-field microscopy of peripheral blood smear, Wright- or Giemsa-stained blood smear, PCR testing, OR serologic assays to detect Borrelia-specific IgG antibodies meet coverage criteria.

IFA for IgM for Borrelia or culture testing does NOT meet coverage.

West Nile virus (WNV) - Covered tests: For suspected WNV, IFA for WNV-specific IgM in serum or CSF AND confirmatory PRNT meet coverage criteria.

NAAT for WNV or IFA for WNV-specific IgG in serum or CSF does NOT meet coverage.

Yellow fever virus (YFV) - Covered tests: For suspected YFV, NAAT OR serologic assays to detect virus-specific IgM and IgG antibodies, plus confirmatory PRNT meet coverage criteria.

Zika virus - Covered tests (pregnancy/infant contexts): Zika NAAT meets coverage for: (a) symptomatic pregnant individuals up to 12 weeks after symptom onset with relevant travel/sexual exposure; (b) infants born to individuals who tested positive for Zika during pregnancy; (c) infants born with signs of congenital Zika syndrome whose birthing parent traveled to risk areas during pregnancy. For pregnant individuals with fetal ultrasound findings consistent with congenital Zika, maternal serum/urine NAAT and maternal serum IgM testing plus confirmatory PRNT meet coverage.Up to 12 weeks for symptomatic pregnant individuals

NAAT and/or IgM testing for non-pregnant symptomatic individuals does NOT meet coverage.

inv-02: Disease-specific diagnostic criteria and recommended testing modalities

Covered diagnostic approaches and situational uses as cited from CDC, IDSA/ASM, and cited studies

Malaria diagnostics: Microscopy (blood smear) is the gold standard and should be performed immediately when ordered; RDTs (e.g., BinaxNOW) are useful where microscopy is not immediately available but have lower sensitivity (example: 84.2%) and can misclassify species; PCR/NAAT is more sensitive and useful to confirm species and detect mixed infections but not usually timely for acute management.RDT sensitivity ~84.2% reported

Confirm RDT results by microscopy as soon as possible.

Babesiosis diagnostics: qPCR has high sensitivity (96.2%) and moderate specificity (70.5%); can be used with or in conjunction with microscopy and serology; consider qPCR for blood donor screening and when conventional tests are negative.sensitivity 96.2%, specificity 70.5%

Multiple smears may be needed; reference lab confirmation recommended.

inv-03: Pathogen-specific testing recommendations

Testing recommendations by pathogen (covered when appropriate specimen and timing align with recommended modality):

Borrelia species (non-Lyme relapsing fever): NAAT and culture or serologic testing recommended; optimum specimens include blood or body fluids for NAAT and serum for culture/serology.

Borrelia miyamotoi: Primary test: NAAT on blood; serology via EIA for recombinant GlpQ antigen using serum also noted.

Anaplasma phagocytophilum: Primary test: NAAT on blood; alternatively Wright/Giemsa stain in first week; serology with acute and convalescent IFA IgG titers using serum; IHC for tissue specimens when indicated.PCR within first week recommended

Optimum specimen: blood; consider bone marrow/autopsy tissue for IHC when indicated.

The policy explicitly lists several serologic methods and nucleic acid tests that DO NOT MEET COVERAGE for specific pathogens. Examples include: Babesia (IgG or IgM IFA assays do not meet coverage) and Dengue (IgG ELISA or hemagglutination testing do not meet coverage). For Ehrlichia/Anaplasma, an IFA for IgM and standard blood culture are not covered. For Plasmodium (malaria), NAAT and antibody IFA testing do not meet coverage. For Rickettsial diseases, NAAT, standard blood culture, and IFA for IgM are listed as noncovered modalities. The policy also specifies that NAAT and/or IgM testing for non-pregnant symptomatic Zika individuals does not meet coverage. Providers should therefore order the test modalities specified as covered for each suspected pathogen and avoid the listed noncovered assays unless otherwise justified by clinical context.

These noncoverage statements are itemized within the reimbursement criteria so that the preferred and acceptable diagnostic approaches (e.g., microscopy, targeted NAAT, acute/convalescent IFA IgG where appropriate) are used according to the pathogen-specific recommendations and timing indicated elsewhere in the policy.

The document notes that the FDA has approved the BinaxNOW Malaria rapid diagnostic test (RDT) but highlights important performance limitations: reported sensitivity is approximately 84.2% and the assay can misclassify Plasmodium falciparum as non-falciparum. The policy cites concerns about use in non-endemic areas and potential false-positives (e.g., Salmonella typhi cross-reactivity) that may affect diagnostic accuracy and downstream management.

Microscopy (stat thick and thin blood smear) is designated as the gold standard for malaria diagnosis and should be performed immediately when malaria is suspected. Rapid diagnostic tests (RDTs) such as BinaxNOW may be used only when microscopy is not immediately available, but all RDT results—positive or negative—must be confirmed by microscopy as soon as possible. The policy further states that PCR/NAAT, while more sensitive and useful for species confirmation and detecting mixed infections, is typically not available quickly enough for initial acute management and therefore should not replace timely microscopy for initial diagnosis.

For Babesia, serologic testing (acute and convalescent IFA IgG titers) is not recommended for acute infection. The policy identifies NAAT (PCR/qPCR) and examination of Giemsa- or Wright-stained blood smears as the primary approaches for acute babesiosis; serology may be of limited utility because it does not reliably distinguish acute from past infection.

The policy states that PCR is not recommended for diagnosis of West Nile virus (WNV) in immunocompetent patients because viral RNA is typically undetectable shortly after symptom onset. Instead, WNV diagnosis relies primarily on detection of virus-specific IgM antibodies in serum or CSF with confirmatory PRNT as indicated; PCR may be reserved for immunocompromised patients or selected clinical circumstances.

Although FDA-approved for hospital and commercial laboratory use, the BinaxNOW Malaria RDT is not approved for use in individual or physician office settings. The policy emphasizes that RDTs should be performed in appropriate laboratory settings and that their limited sensitivity and potential for species misclassification require confirmatory microscopy and appropriate laboratory infrastructure for accurate interpretation.

The policy cites multiple reference sources and external resources (e.g., UpToDate reviews, WHO guidance, and primary literature) to support diagnostic recommendations, but these reference and test-catalog entries do not themselves state additional explicit coverage exclusions beyond those enumerated in the policy. Providers should follow the policy’s coverage rules while consulting the listed references for clinical and laboratory guidance.

Testing for the listed vector-borne infections during a routine general examination in an asymptomatic individual without abnormal findings is not medically necessary and does not meet coverage criteria. Providers should not order screening panels for babesiosis, chikungunya, CTF, dengue, ehrlichiosis/anaplasmosis, malaria, rickettsial disease, TBRF, WNV, YFV, or Zika virus in asymptomatic patients absent specific clinical indications.

Routine testing for Zika or dengue is not recommended for asymptomatic patients, including asymptomatic pregnant individuals living in or traveling to the U.S. and its territories. For symptomatic pregnant individuals or those with relevant exposures, Zika NAAT and concurrent dengue/Zika testing windows and specimen types are specified; however, routine asymptomatic screening for these arboviruses is not supported by the guidance cited.

The policy warns that isolated single serologic titers—particularly IgM or a single mildly elevated IgG—can be nondiagnostic in endemic areas due to persistence of antibodies and cross-reactivity. Where serology is used for confirmation (for example, rickettsial diseases), the policy emphasizes paired acute and convalescent specimens demonstrating a fourfold rise in IgG titer rather than relying on a single titer or IgM alone.

The policy includes citations and links to external test catalogs and literature to inform clinical practice, but the referenced materials themselves do not add separate 'not medically necessary' statements beyond those contained in the policy. Follow the policy’s explicit coverage and noncoverage rules while using the referenced resources for clinical details and laboratory ordering instructions.

Procedure and Test Codes

Covered / Not covered test modalities by pathogenmixed

No codes listed

Applicable CPT/HCPCS Procedure CodesCPT

86280	Hemagglutination inhibition test (HAI).
86382	Neutralization test, viral.
86619	Antibody; Borrelia (relapsing fever).
86666	Antibody; Ehrlichia.
86750	Antibody; Plasmodium (malaria).
86753	Antibody; protozoa, not elsewhere specified.
86757	Antibody; Rickettsia.
86788	Antibody; West Nile virus, IgM.
86789	Antibody; West Nile virus.
86790	Antibody; virus, not elsewhere specified.

1–10 of 13

1/2

Serology, culture, smear CPT codesCPT

86280	Hemagglutination inhibition test (HAI).
86382	Neutralization test, viral.
86619	Antibody; Borrelia (relapsing fever).
86666	Antibody; Ehrlichia.
86750	Antibody; Plasmodium (malaria).
86753	Antibody; protozoa, not elsewhere specified.
86757	Antibody; Rickettsia.
86788	Antibody; West Nile virus, IgM.
86789	Antibody; West Nile virus.
86790	Antibody; virus, not elsewhere specified.

1–10 of 13

1/2

Antigen and molecular detection CPT/HCPCS and Proprietary U-codesmixed

87449	Infectious agent antigen detection by immunoassay technique; qualitative or semiquantitative; not otherwise specified, each organism.
87468	Infectious agent detection by nucleic acid (DNA or RNA); Anaplasma phagocytophilum, amplified probe technique.
87469	Infectious agent detection by nucleic acid (DNA or RNA); Babesia microti, amplified probe technique.
87478	Infectious agent detection by nucleic acid (DNA or RNA); Borrelia miyamotoi, amplified probe technique.
87484	Infectious agent detection by nucleic acid (DNA or RNA); Ehrlichia chaffeensis, amplified probe technique.
87662	Infectious agent detection by nucleic acid (DNA or RNA); Zika virus, amplified probe technique.
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism.
87899	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; not otherwise specified.
0043U	Proprietary test: Tick-Borne Relapsing Fever Borrelia (TBRF) ImmunoBlots IgM Test (IGeneX Inc) - antibody detection to 4 recombinant proteins.
0044U	Proprietary test: Tick-Borne Relapsing Fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG (IGeneX Inc).

Referenced Laboratory Test IDsmixed

LCMAL

Malaria, Molecular Detection, PCR (Test ID)

inv-20: Zika NAAT testing window — Up to 12 weeks for symptomatic pregnant individuals

Zika NAAT testing windowUp to 12 weeks after symptom onset for symptomatic pregnant individuals with relevant travel or sexual exposure

Other covered Zika NAAT contextsInfants born to individuals who tested positive for Zika during pregnancy; infants with signs of congenital Zika syndrome if parent traveled to risk areas

Specimen types notedCDC/WHO guidance supports NAAT on serum and urine for Zika detection in pregnant patients

inv-21: Repeat malaria smear guidance — repeat up to three times within three days if clinically indicated

Repeat malaria smear frequencyMay be repeated up to three times within three days if initial microscopy is negative in suspected malaria cases

Provider Actions, Documentation, and Billing Guidance

Note

Coverage-dependent testing requirement

Testing that meets coverage is dependent on the member's specific benefit coverage and applicable government policies. Providers must order tests aligned with the suspected pathogen and follow specimen type and timing guidance in the policy and laboratory-specific instructions.

Coverage-dependent: Order tests that are listed as MEETS COVERAGE CRITERIA for the suspected condition (e.g., NAAT/ smear microscopy for malaria; NAAT/IFA for dengue as specified).
Document specimen type and collection timing relative to symptom onset (acute vs convalescent) and follow lab-specific specimen handling instructions.
When using laboratory-developed tests (LDTs), ensure they are validated and performed in-house under CLIA high-complexity rules.

Prior Authorization

Prior authorization — no explicit requirement found

This policy contains no explicit prior authorization requirement. Verify payer-specific prior authorization rules before ordering as payer practices may vary.

Background and Scope

Background: Arthropod vectors—mosquitoes, ticks, fleas, and mites—transmit a broad range of pathogens including arboviruses (e.g., Zika, West Nile, dengue, chikungunya, yellow fever), protozoa (e.g., Plasmodium spp. causing malaria, Babesia spp.), and bacterial agents (e.g., Rickettsia, Ehrlichia/Anaplasma, Borrelia species). Diagnostic approaches vary by agent and clinical context and include microscopy (e.g., Giemsa- or Wright-stained blood smears for malaria and babesiosis), NAAT/PCR for acute detection and species confirmation, and serologic assays (IFA, MAC-ELISA, PRNT) with paired acute/convalescent testing when indicated. The policy outlines which modalities meet coverage for each pathogen and where certain tests are explicitly noncovered.

Abbreviations and Definitions

inv-48: Selected abbreviations (NAAT, IFA, MAC-ELISA, PRNT, etc.)

NAATNucleic acid amplification testing (NAAT)

IFAIndirect immunofluorescence antibody (IFA)

MAC-ELISAIgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA)

PRNTPlaque reduction neutralization test (PRNT)

RDTRapid diagnostic testing (RDT)

inv-49: NAAT definition and scope

NAAT definitionIncludes PCR, real-time PCR (RT-PCR), and other enzyme-dependent amplification assays to detect pathogen DNA or RNA

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyTesting for Vector-borne Infections — Coverage and Clinical-Laboratory Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder pathogen-specific tests consistent with the listed coverage criteria and document specimen type and timing relative to symptom onset.

SourceLink

On This Page

Tickborne rickettsial diseases:

IFA is the standard reference despite insensitivity in the first week; collect acute and convalescent specimens 2–4 weeks apart and document a fourfold rise in IgG for confirmation. PCR of whole blood may be useful for ehrlichiosis and anaplasmosis early in illness; PCR sensitivity is low for Rickettsia rickettsii except in severe disease. Microscopy for morulae can support ehrlichiosis/anaplasmosis diagnosis.

fourfold rise in antibody titer

Culture is rarely used due to specialized requirements.

Tickborne relapsing fever (TBRF): Direct microscopy (dark-field or stained blood smears) is useful early due to high spirochetemia (>10^6 spirochetes/ml); serology is not standardized and may require convalescent sampling (>21 days) for interpretation; cross-reactivity with Lyme tests can occur.>10^6 spirochetes/ml more readily detectable by microscopy

Consider clinical and geographic context when interpreting microscopy.

Arboviral infections (WNV, YFV, dengue, Zika, chikungunya): WNV: IgM in serum/CSF is primary diagnostic test; NAAT often not suitable due to low viremia except in immunocompromised. Yellow fever: isolate virus or perform NAAT early; confirm with PRNT due to flavivirus cross-reactivity. Dengue: use molecular and serologic testing within first 7–10 days (NS1 or NAAT early), then serology/PRNT for confirmation. Zika: in pregnancy, NAAT (serum and urine) and dengue NAAT/IgM for symptomatic cases; Zika IgM not recommended for routine use due to persistence and cross-reactivity; repeat/confirm positive NAATs to rule out false positives.dengue testing window: <=7–10 days for molecular/NS1; PRNT for confirmation

For congenital Zika, test infants when maternal evidence or clinical findings suggestive of syndrome.

IDSA/ASM tick-borne testing specifics: IDSA/ASM mapping shows primary and alternate diagnostic tests and optimum specimens: e.g., B. miyamotoi primary test NAAT (blood); relapsing fever borreliae primary test darkfield/stained blood smears; Anaplasma/Ehrlichia primary NAAT on whole blood with stains in first week; serology (acute and convalescent IFA) for several agents.

Specimen types specified (blood, serum, bone marrow, body fluids) depending on agent.

Primary test: NAAT on whole blood; Wright/Giemsa stain in first week; serology via acute and convalescent IFA IgG titers; IHC for tissue specimens when indicated.

Optimum specimen: whole blood for NAAT.

Rickettsia spp (including RMSF): Serology with acute and convalescent IFA for IgM/IgG using serum is recommended; NAAT and immunohistochemical staining of skin biopsy or autopsy tissues may be used; optimum specimens include skin biopsy (maculopapule/eschar) or autopsy tissues.fourfold rise in IgG between acute and convalescent sera

IFA is insensitive in first week; pair sera 2–4 weeks apart for confirmation.

Babesia spp: Primary microscopy: Giemsa/Wright stains of thin and thick blood smears (Giemsa preferred); NAAT is primary test for acute infection; serology (acute/convalescent IFA IgG) is not recommended for acute infection but may help detect low parasitemia.

Optimum specimen: whole blood; serology not recommended for acute infection.

Malaria (Plasmodium spp): Stat microscopic examination of Giemsa-stained thick and thin blood films with repeat testing every 12–24 h for up to 3 exams before ruling out; RADTs may be used but require confirmatory films; PCR from reference labs can detect and differentiate species.repeat smears every 12–24 h up to 3 exams

Use PCR for species confirmation and detection of mixed infections.

Dengue and Zika (arboviruses): Detection of viral RNA by NAAT preferred for acutely ill patients; NS1 antigen acceptable alternative for dengue early in illness; serologic testing (IgM/IgG) is complicated by cross-reactivity and may require PRNT for confirmation; consider specimen timing and pregnancy implications per CDC/WHO guidance.dengue/NS1 or NAAT within first 7–10 days

For Zika in pregnancy, perform serum and urine NAAT and dengue+Zika NAAT concurrently; repeat positive Zika NAAT on newly extracted RNA to rule out false positives.

West Nile Virus: Diagnosis typically by virus-specific IgM and/or IgG in serum or CSF; PCR may be used for immunosuppressed patients; serology subject to cross-reactivity and prolonged IgM positivity; confirm with PRNT when needed.

Repeat testing and paired sera may be required; NAAT often insensitive in typical immunocompetent cases.

Role of RDTsRapid immunochromatographic diagnostic tests may be used when microscopy unavailable but require confirmation

NAAT/IFA for PlasmodiumNAAT or IFA for Plasmodium antibodies DOES NOT MEET COVERAGE for initial diagnosis

inv-22: No additional specifications provided in these code chunks

No additional thresholds specifiedNo other numeric thresholds or repeat limits are provided in the cited code chunks

Refer to pathogen-specific nodesSee individual pathogen coverage criteria for modality-specific limits or exclusions

Procedure codes unchangedNo numeric threshold entries associated with procedure codes in these chunks

No explicit PA requirement stated in the policy text.
Always check the member's Blue Cross Blue Shield - Tennessee benefit and any PA portal or payer-specific guidance prior to sending specimens or ordering specialized testing.

Documentation Required

Diagnostic testing workflow for malaria

For suspected malaria, immediate microscopic examination of Giemsa- or Wright-stained thick and thin blood smears is the preferred initial diagnostic approach; do not send out initial smears when rapid local microscopy is required for acute management.

Preferred initial test: Stat blood-smear microscopy (thick and thin); repeat every 12–24 hours up to three times within 72 hours if initial smear is negative and suspicion remains.
If microscopy is unavailable, use a rapid diagnostic test (RDT) but confirm both positive and negative RDT results with microscopy as soon as possible.
PCR/NAAT is useful for species confirmation and detection of low-level parasitemia but is not appropriate as the sole first-line test when rapid results are required for acute management.

Billing Rule

Procedure codes noted — verify prior authorization policies per payer

Procedure codes listed in the policy are provided as a reference; verify payer-specific prior authorization requirements and coding guidance before claim submission.

Procedure codes in the policy may not be exhaustive; confirm with the payer's billing guidance.
Check Blue Cross Blue Shield - Tennessee prior authorization policies and code edits before ordering or billing.

Billing Rule

Procedure codes referenced for claims/prior authorization

Use the listed CPT/HCPCS and Proprietary U-codes when submitting claims for the corresponding tests; group codes by billing category when preparing claims.

Examples: 87469 (Babesia NAAT), 87484 (Ehrlichia NAAT), 86750/86753 (Plasmodium antibodies), 0043U/0044U (proprietary TBRF immunoblots).
Include appropriate specimen and testing details in the claim to support medical necessity.

Note

Lab test citation

Reference to a laboratory test catalog entry is provided for PCR-based malaria testing; follow the laboratory's specific ordering and specimen instructions.

Test citation: Test ID: LCMAL Malaria, Molecular Detection, PCR, Varies (Mayo Clinic Laboratories).
Lab link (example): https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/87860 — follow lab-specific specimen, timing, and transport guidance.

Denial Risk

Risks with low-sensitivity tests

Be cautious when relying on tests with known low sensitivity or specificity; use confirmatory testing or alternative methods when appropriate to avoid false negatives/positives and potential denials.

BinaxNOW malaria RDT reported sensitivity ~84.2% and may misclassify species; Salmonella typhi can cause false positives.
IgM serologies (e.g., rickettsial IgM) are prone to false positives; confirm with paired sera and IgG fourfold rise when required.

Denial Risk

Timeliness risk for PCR in acute malaria

PCR/NAAT may provide higher sensitivity but often has longer turnaround times; avoid relying on PCR alone for acute malaria diagnosis when immediate results are needed for treatment.

Use PCR for species confirmation or when microscopy/RDT are inconclusive or parasitemia is very low.
Do not send out smears or rely on send-out PCR when rapid on-site microscopy is indicated for initial acute management.

Note

Conflict with government policy may drive denial

If a conflict exists between this medical policy and an applicable government policy (LCD/NCD or state Medicaid), the government policy supersedes and may drive coverage determinations or denials.

When Medicare/Medicaid rules differ from this policy, follow the applicable LCD/NCD or state Medicaid guidance for the member.
Confirm coverage determinations using the CMS Medicare Coverage Database or the applicable state Medicaid website when needed.

Billing Rule

Procedure codes appearing in Medical Policy

Procedure codes appearing in this medical policy are provided only as a general reference tool and may not be all‑inclusive; use the codes listed in the policy along with payer-specific coding guidance when submitting claims.

The policy lists CPT/HCPCS and proprietary U-codes relevant to vector‑borne and travel‑related infectious disease testing.
Always verify code applicability and bundling rules with Blue Cross Blue Shield - Tennessee prior to billing.

Note

No denial-triggering authorization language present

This document does not contain explicit prior‑authorization language that would automatically trigger denial; however, coverage is determined by meeting the policy's clinical indications and payer rules.

Absence of authorization language in this policy does not replace payer-specific PA requirements — always confirm.
Denials may still occur if testing does not meet the clinical indications listed in the policy (e.g., asymptomatic screening without abnormal findings is not covered).

Documentation Required

Rickettsial IFA documentation note

For rickettsial disease serology, IFA IgG testing is limited to two units and paired acute and convalescent sera with a fourfold rise in IgG titer are required to confirm acute infection; document justification when ordering and interpreting IgG/IgM assays.

IFA IgG for rickettsial disease: Meets coverage criteria but limited to two units.
Collect an acute specimen early in illness and a convalescent specimen 2–4 (or 2–6) weeks later; require a ≥4-fold rise in IgG to confirm acute infection.
IgM assays are less specific and prone to false positives; document rationale if IgM is used.

Documentation Required

Specimen and method documentation

Document specimen type, collection timing relative to symptom onset, and the specific testing method used (e.g., NAAT, microscopy, IFA, culture) in the medical record to support medical necessity and claims.

Record specimen source (e.g., whole blood, serum, CSF, tissue), collection date/time, and symptom onset date.
Follow laboratory-specific specimen handling and transport instructions to preserve specimen integrity.

Documentation Required

Specimen timing and paired sera documentation

When serology is indicated (e.g., rickettsial diseases, ehrlichiosis/anaplasmosis), collect paired acute and convalescent sera at appropriate intervals and document timing to demonstrate serologic conversion or a fourfold rise in IgG titer.

Acute specimen: collect early after symptom onset (first week when possible).
Convalescent specimen: collect 2–4 weeks (or up to 2–6 weeks for some rickettsial infections) after the acute specimen.
A fourfold rise in IgG between acute and convalescent specimens is required to confirm recent infection.

Note

Links to external lab test catalog (Mayo Clinic Laboratories)

External laboratory test catalogs are linked for provider reference; follow those lab-specific ordering and specimen instructions when sending tests to reference laboratories.

Example lab resource: Mayo Clinic Laboratories Test ID LCMAL Malaria, Molecular Detection, PCR. Catalog: https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/87860
Use laboratory catalog instructions for specimen type, volume, anticoagulant, and transport conditions.

Step Therapy

Step therapy / testing sequence

No step therapy or testing sequence requirements are specified in this policy; follow the clinical guidance for preferred diagnostic modalities and payer rules.

Policy does not mandate a stepwise testing sequence (e.g., must try test A before test B).
Providers should follow recommendations for preferred initial tests (e.g., microscopy for malaria) and use confirmatory testing as clinically indicated.

Documentation Required

Preferred initial test for malaria

Preferred initial test for malaria is immediate expert microscopy (thick and thin smears); RDTs are acceptable only when microscopy is unavailable and must be confirmed by microscopy as soon as possible.

Perform stat smear microscopy with results available within hours for acute management.
If microscopy is not available, use an FDA-approved RDT (e.g., BinaxNOW) but confirm both positive and negative results with microscopy promptly.

Specimen scopeCan be performed on serum, whole blood, tissue, CSF, and FFPE specimens

Performance noteNAATs are specific and sensitive but availability and cost vary by laboratory

inv-50: IFA definition and cross-reactivity note

IFA definitionIndirect immunofluorescence antibody assay used to detect IgG/IgM antibodies reactive against pathogens

Cross-reactivity caveatIFA can cross-react with prior vaccination or infection and often requires acute and convalescent samples to demonstrate a fourfold rise

Use caseIFA is standard reference for several rickettsial diagnoses despite early insensitivity

inv-51: IFA abbreviation entry

IFAIndirect immunofluorescence antibody

Common targetsUsed to detect IgG and IgM antibodies to multiple vector-borne pathogens

Diagnostic requirementOften requires paired acute and convalescent sera for confirmation

inv-52: PCR / NAAT abbreviation entry

PCR / NAATPolymerase chain reaction (PCR) as a form of NAAT to detect pathogen nucleic acid

Acronym usagePCR and NAAT are used interchangeably for molecular detection methods in the policy

Specimen considerationsSpecimen choice affects sensitivity (e.g., whole blood vs tissue) and NAAT window varies by pathogen

inv-53: NAAT usage and limitation note

NAAT usagePreferred detection method for acute infection for many pathogens due to sensitivity

LimitationPeriod of RNA/DNA detectability is limited for some arboviruses, so timing of specimen collection is critical

Lab availabilitySome NAATs may not be available at all laboratories and can be costly

inv-54: Serology (acute/convalescent) definition

Serology (acute/convalescent)Measurement of antibody titers in paired acute and convalescent sera to document seroconversion or a fourfold rise in IgG titer to confirm recent infection

TimingCollect acute and convalescent specimens 2–4 weeks apart for many tickborne and arboviral infections

Interpretation caveatSingle elevated IgG or IgM may be nondiagnostic due to cross-reactivity or persistent antibodies

inv-55: Laboratory-developed test (LDT) definition

Laboratory-developed test (LDT)A test developed and validated within a laboratory and performed in-house; regulated by CMS as high-complexity under CLIA '88

Regulatory statusLDTs are not FDA-approved or cleared but may be used clinically after laboratory validation

Operational noteLDTs require local validation and are subject to CLIA requirements

inv-56: Rapid diagnostic test (RDT) definition and example

Rapid diagnostic test (RDT)An in vitro qualitative immunochromatographic assay (example: BinaxNOW Malaria) approved for use by hospital and commercial laboratories

LimitationsRDTs can have lower sensitivity and may misclassify species (BinaxNOW reported sensitivity example cited) and often require confirmatory microscopy

Regulatory noteBinaxNOW Malaria RDT is not approved for individual/physician office use

inv-57: LCMAL Malaria, Molecular Detection, PCR — referenced test ID

LCMAL Test IDLCMAL — Malaria, Molecular Detection, PCR (Test ID listed as 'Varies' in test catalog citation)

PurposeReferenced molecular PCR test for detection of Plasmodium species

Catalog noteListed in external lab test catalog entry cited in the policy